In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
mRNA-based vaccine specialist BioNTech and its partner Pfizer have released strong new data for its Omicron-adapted bivalent booster. 4 November 2022
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim has appointed a new chief medical officer, Lykke Hinsch Gylvin. 4 November 2022
Pharmaceutical
Japanese drugmaker Kissei Pharmaceutical has entered into a license agreement with Synmosa Biopharma for the development and commercialization rights in Taiwan for the GnRH antagonist linzagolix that was discovered by Kissei. 4 November 2022
Biotechnology
US biotech major Amgen reported its quarterly financial results late Thursday. 4 November 2022
Pharmaceutical
Shares of Swiss biopharma Kinarus Therapeutics Holding ( were down 13% by midday after it confirmed plans to focus on clinical trials of its lead candidate KIN001 in ophthalmic and pulmonary fibrosis indications, and to refocus its capital resources and financing efforts to drive these programs. 4 November 2022
Biotechnology
Struggling in the wake of the discontinuation of ziritaxestat, Belgian biotech Galapagos is to undertake a radical restructuring aimed at jump-starting the business. 4 November 2022
Biotechnology
Shares of US gene and cell therapy company Abeona Therapeutics hit a high of $4.80 yesterday but closed 13% lower at $3.87, after it announced positive top-line data from its pivotal Phase III VIITAL study assessing the safety and efficacy of EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), as well as a $35 million financing. 4 November 2022
Biotechnology
Shares of US mRNA-focussed biotech Moderna slid more than 11% pre-market yesterday, before recovering to close down 0.76% at $147.50, as it reported financial results. 4 November 2022
Pharmaceutical
Special purpose acquisition company (SPAC) deals were October's order of the month in the pharmaceutical M&A market. 3 November 2022
Generics
Israeli generics company Teva Pharmaceutical Industries was trading more than 2% lower late on Thursday, following the firm’s presentation of its third quarter 2022 financial results. 3 November 2022
Biotechnology
Germany’s Affimed saw its shares leap more than 17% to $1.98 today, after it revealed a collaboration with privately held US biotech Artiva Biotherapeutics. 3 November 2022
Biotechnology
Revenues at Regeneron came in at $2.9 billion in the third quarter of 022, slightly higher than most analysts’ were expecting, but still 15% lower than the same period of 2021. 3 November 2022
Pharmaceutical
A monkeypox vaccine may soon be available from India, as six companies have been identified by The Indian Council of Medical Research (ICMR) and given the go-ahead to make the vaccine, reports The Pharma Letter’s local correspondent. 3 November 2022
Generics
According to the charity Médecins Sans Frontières (MSF), negotiations between the UK and India on a Free Trade Agreement (FTA) were formally launched in January 2022 and are currently accelerating, with high-level meetings between the two governments scheduled this November on the side-lines of the G20 Summit in Indonesia, according to reports. 3 November 2022
Biotechnology
Australia’s CSL Limited has sought to shed light on the promise of its pipeline at its annual R&D investor briefing. 3 November 2022
Biotechnology
Times are tough for cell medicine specialist Rubius Therapeutics, with the firm announcing plans to slash its workforce by 84%, part of a drastic effort to avoid bankruptcy. 3 November 2022
Biotechnology
Ireland-incorporated biotech Alkermes’ shares closed up 3.5% at $24.06 yesterday, as it pleased investors when it revealed that it is to explore separating its commercial-stage neuroscience business and development-stage oncology business. 3 November 2022
Biotechnology
Arcturus Therapeutics, a US messenger RNA (mRNA) company focused on the development of infectious disease vaccines, saw its shares rocket up nearly 24% to $22.63 yesterday on news of what could be an up to $4.5 billion deal relating to its technology. 3 November 2022
Pharmaceutical
Gianfranco Nazzi has stepped down effective November 2 from his role as chief executive of Spanish skincare specialist Almirall (ALM: MC) to pursue new professional opportunities. 3 November 2022
Biotechnology
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published an evidence report on the comparative clinical effectiveness of hemophilia treatments. 2 November 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze